| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1472-6483(11)60212-5 |
| P698 | PubMed publication ID | 12537777 |
| P2093 | author name string | Pedro N Barri | |
| Buenaventura Coroleu | |||
| Rosa Tur | |||
| Francisca Martinez | |||
| P2860 | cites work | Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. | Q50723601 |
| Embryo implantation and GnRH antagonists: GnRH antagonists in ART: lower embryo implantation? | Q50724089 | ||
| Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. | Q50761617 | ||
| Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility | Q71736673 | ||
| Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks | Q73149626 | ||
| Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers | Q73261975 | ||
| Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation | Q73296595 | ||
| Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. | Q73942932 | ||
| Comment on the debate article: embryo implantation: the Rubicon for GnRH antagonists | Q73959127 | ||
| Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation | Q74247852 | ||
| Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better? | Q74452649 | ||
| The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg | Q77525121 | ||
| Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group | Q22253231 | ||
| Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix | Q31864713 | ||
| Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation | Q31864785 | ||
| Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists | Q33779784 | ||
| Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists | Q33930196 | ||
| The LHRH antagonist cetrorelix: a review | Q34022996 | ||
| Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists | Q34201717 | ||
| Gonadotropin-releasing hormone antagonist: how good is the new hope? | Q34276427 | ||
| The role of gonadotropin-releasing hormone antagonists in in vitro fertilization | Q34419439 | ||
| Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation | Q39225737 | ||
| The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. | Q41019820 | ||
| Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation | Q43559178 | ||
| Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix | Q43559187 | ||
| Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran | Q43564879 | ||
| Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial | Q43594492 | ||
| Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). | Q43811117 | ||
| The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women | Q46055577 | ||
| A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix | Q48891901 | ||
| Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study | Q48892084 | ||
| Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). | Q48898305 | ||
| High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles | Q48910001 | ||
| Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation | Q49106785 | ||
| P304 | page(s) | 14-19 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Reproductive BioMedicine Online | Q15762964 |
| P1476 | title | The role of GnRH antagonists in assisted reproduction | |
| P478 | volume | 5 Suppl 1 |
| Q44678765 | Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study. |
| Q44624341 | Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment |
| Q44557473 | IVF outcome in anovulatory infertility (WHO group 2)--including polycystic ovary syndrome--following previous unsuccessful ovulation induction |
| Q57092258 | Transition from blastomere to trophectoderm biopsy: comparing two preimplantation genetic testing for aneuploidies strategies |
Search more.